

Late-stage program in glaucoma with NDA¹ filing targeted for H1 2026



Commercial-stage assets and R&D collaborations already in place



Global reach with top-tier worldwide licensees



Significant market opportunity: 80 mn glaucoma patients worldwide²



Revenue-generating ophthalmology biotech developing sight-saving therapies

A Proven Track Record

Two commercialized products in the U.S., one in China

Deals in the U.S., Japan, China, and globally with Tier 1 companies

NCX 470 : two positive Phase 3 trials

U.S. NDA in preparation for FDA submission in H1 2026

Global partnerships with Kowa and Ocumension Therapeutics

Strategic Transaction Capability

Corporate team with significant transaction and financing experience

Exploring future growth opportunities

Large Potential Market for NCX 470


~\$7 bn worldwide glaucoma market

Successful track record of VYZULTA® under partnership with Bausch + Lomb

Near Term Value through NCX 470, a Derisked Product Candidate with Global Potential

		Preclinical	Clinical	NDA	Marketed	Partner	
VYZULTA®	Glaucoma and Ocular Hypertension						Worldwide ³
ZERVIAE®	Allergic Conjunctivitis					 	U.S. China
NCX 470	Glaucoma and Ocular Hypertension	U.S. and China				 	China, Korea and Southeast Asia U.S. and all other territories
NCX 1728	Glaucoma (incl. Neuroprotection)						Research and global licensing option agreement
	NO-donating PDE 5 inhibitor						

Global Licensing of NCX 470



1- New Drug Application
2- World Glaucoma Association website: "World Glaucoma Association" What is glaucoma?
3- Revenue sold to Soleus Capital in October 2024